Pharmacogenomics of antiepileptic drug mood stabilizer treatment response in bipolar disorder: A MoStGen Consortium study - PubMed
2 days ago
- #Bipolar Disorder
- #Mood Stabilizers
- #Pharmacogenomics
- The Mood Stabilizer Genomics (MoStGen) Consortium studied pharmacogenomic and clinical predictors of response to antiepileptic drug mood stabilizers (AMS) in bipolar disorder (BD).
- Genome-wide association analyses identified significant associations for lamotrigine (LTG) treatment response with SNPs in ROBO2 (rs985123, p=1.9E-10) and POLR1E (p=2.53E-06).
- No significant associations were found for overall AMS or valproic acid (VPA) treatment response.
- Polygenic score (PGS) analyses indicated a polygenic signal for AMS treatment response and a nominal association between epilepsy PGS and better AMS response (p=0.024).
- The study provides insights into genetic contributions to AMS treatment outcomes, particularly LTG response, aiding in the development of more precise BD treatments.